[Rhythmical and cardiovascular disorders of neuroendocrine origin. Induction and experimental pharmacological reversion. II (author's transl)].
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000638:Amiodarone / Q000627:therapeutic use; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000188:drug therapy / Q000209:etiology*; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000209:etiology*; D002415:Cats; D004700:Endocrine System Diseases / Q000150:complications*; D009422:Nervous System Diseases / Q000150:complications*; D011217:Practolol / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D011433:Propranolol; D011802:Quinidine; D000638:Amiodarone; D011217:Practolol
Trastornos del ritmo y cardiocirculatorios neuroendocrinógenos. Inducción y reversión farmacológica experimental. II